Edward R. Sauter

No ORCID on file · 1 paper in corpus · active 2011

Study types

  • article 1
article 2011
·doi:10.1186/1756-0500-4-152

BACKGROUND: In preclinical studies, müllerian inhibiting substance (MIS) has a protective affect against breast cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or precancerous lesions. …